ABBV - AbbVie Inc.

NYSE - Nasdaq Real Time Price. Currency in USD
-0.82 (-1.05%)
As of 10:26AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close77.98
Bid77.22 x 800
Ask77.19 x 1400
Day's Range76.86 - 78.21
52 Week Range75.77 - 107.25
Avg. Volume6,400,820
Market Cap114.055B
Beta (3Y Monthly)0.99
PE Ratio (TTM)21.08
EPS (TTM)3.66
Earnings DateApr 25, 2019
Forward Dividend & Yield4.28 (5.31%)
Ex-Dividend Date2019-04-12
1y Target Est92.18
Trade prices are not sourced from all markets
  • CNW Group22 minutes ago

    Health Canada Approves SKYRIZI™ (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis

    Health Canada Approves SKYRIZI™ (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis

  • Investing.comyesterday

    AbbVie Falls 3% - AbbVie (NYSE:ABBV) fell by 3.07% to trade at $77.754 by 13:29 (17:29 GMT) on Wednesday on the NYSE exchange.

  • Is TG Therapeutics a Buy?
    Motley Fool2 days ago

    Is TG Therapeutics a Buy?

    The stock price of this clinical-stage biotech has nearly doubled so far in 2019.

  • Top Marijuana Stocks That Pay Dividends
    Investopedia2 days ago

    Top Marijuana Stocks That Pay Dividends

    When most people think of marijuana stocks, the last thing they think of is dividends. Furthermore, U.S. investors in the marijuana space tend to currently focus on a handful of Canadian companies which have enjoyed the opportunity to list on U.S. exchanges. The company remains one of the most popular marijuana pharmaceuticals developers.

  • J&J (JNJ) Beats on Q1 Earnings, Ups 2019 Sales Growth View
    Zacks2 days ago

    J&J (JNJ) Beats on Q1 Earnings, Ups 2019 Sales Growth View

    J&J (JNJ) beats estimates for both earnings and sales in the first quarter of 2019 and raises 2019 guidance for operational sales and adjusted operational EPS growth. Shares up in pre-market trading.

  • InvestorPlace2 days ago

    Is AbbVie Stock An Undiscovered Cannabis Play Waiting For Some Attention?

    The market opportunity for cannabis is enormous. According to Grand View Research, the spending is expected to hit a staggering $146.4 billion in the U.S. by the end of 2025.Nowadays there are more publicly traded companies to play this megatrend, including names like Canopy Growth (NYSE:CGC), Aurora Cannabis (NYSE:ACB), Cronos Group (NASDAQ:CRON), and Tilray (NASDAQ:TLRY). Beyond these stocks' extreme volatility, they also fetch sky-high valuations, with price-to-sales multiples often well over 50x.So, is there way to get exposure to the cannabis opportunity -- but not take on too much risk? Interestingly enough, there is one such stock to consider: AbbVie (NYSE:ABBV). It's a company that rarely pops up on many people's radar screen when it comes to cannabis. After all, it's one of the world's largest traditional pharma operators, with roots going back to 1888. Keep in mind that ABBV stock was spun-off from Abbott Laboratories (NYSE:ABT) in 2013.InvestorPlace - Stock Market News, Stock Advice & Trading TipsSo what does ABBV stock have to do with cannabis? Well, consider that the company has a drug on the market, called Marinol. It is based on a compound known as dronabinol, a synthetic form of THC, which is a natural part of the marijuana plant (that is, cannabis sativa). This is what activates the "high." * 7 High-Risk Stocks With Big Potential Rewards Now Marinol has proven to be effective in dealing with the symptoms of a host of terrible diseases. For example, it helps deal with the nausea from chemotherapy and the weight problems resulting from those who suffer from AIDS.Granted, Marinol is not a blockbuster drug. But then again, it does show the promise of cannabis as a treatment. More importantly, as for AbbVie stock, the drug is an indication of the company's ability to push innovation with alternative treatments. In other words, it would not be a surprise that it will go on to leverage this experience to look at more treatments.What's more, the use of cannabis for medical purposes is certainly a major opportunity. There are already 41 countries that allow for this, whether on a federal or state level. Bottom Line on AbbVie StockGranted, it would not be a good idea to invest in AbbVie stock just because it has a cannabis drug. To be sure, as seen with the latest earnings report, the company does have some problems as it issued disappointing guidance. Since early this year, ABBV stock has sunk from $91 to $81.The nagging issue is the company's most important drug, Humira (this is for the treatment of arthritis, plaque psoriasis, Crohn's disease, and ulcerative colitis). For the most part, the growth is slowing. And yes, there are worries about when the U.S. patent protection comes off in 2023. * 8 Risky Stocks to Watch as Earnings Season Kicks Off Despite all this, I still think there is a bullish case for AbbVie stock. One, the company has a decent roster of drug candidates that could move the needle -- and help make up for a shortfall in Humira. For example, it has several immunology treatments (risankizumab and upadacitinib) that should hit the markets this year. Interestingly enough, when it comes to the pipeline, AbbVie has lots of potential with the cancer market. To this end, its drug Imbruvica is likely to spin-off various treatments for the category.And who knows, perhaps there could be potential from cannabis as well? I think so.In the meantime, AbbVie stock sports a dirt-cheap valuation, with the forward price-to-earnings multiple at only 8.6x. Oh, and the dividend is at 5.15%, making it one of the highest among the major pharma companies.Tom Taulli is the author of High-Profit IPO Strategies, All About Commodities and All About Short Selling. Follow him on Twitter at @ttaulli. As of this writing, he did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Internet Stocks to Watch * 7 AI Stocks to Watch with Strong Long-Term Narratives * 10 Dow Jones Stocks Holding the Blue Chip Index Back Compare Brokers The post Is AbbVie Stock An Undiscovered Cannabis Play Waiting For Some Attention? appeared first on InvestorPlace.

  • AbbVie (ABBV) Gains As Market Dips: What You Should Know
    Zacks3 days ago

    AbbVie (ABBV) Gains As Market Dips: What You Should Know

    AbbVie (ABBV) closed at $81.01 in the latest trading session, marking a +0.28% move from the prior day.

  • 8 Dividend Rich Blue Chips to Prosper as Buyback Mania Fades
    Investopedia3 days ago

    8 Dividend Rich Blue Chips to Prosper as Buyback Mania Fades

    If stock buybacks face more restrictions, dividends may rise. Meanwhile, Goldman Sachs says that high dividend stocks should outperform the market.

  • Goldman Sachs's 20 best stocks to invest in now
    Yahoo Finance3 days ago

    Goldman Sachs's 20 best stocks to invest in now

    What are the best stocks to buy after a major rally amid heightened macro risks?

  • The Simple Way You Could Make 10% Each Year With AbbVie
    Motley Fool4 days ago

    The Simple Way You Could Make 10% Each Year With AbbVie

    There's nothing complicated at all about this approach to making a solid profit with one of the top big pharma stocks on the market.

  • Looking for a job? Here's the 2018 median pay at 50 top U.S. companies
    American City Business Journals6 days ago

    Looking for a job? Here's the 2018 median pay at 50 top U.S. companies

    Out of 50 of the largest companies in America, the highest median employee pay in 2018 was at Texas-based oil giants Phillips 66 and Exxon Mobil Corp.

  • Forward Guidance Will Make or Break JNJ Earnings
    InvestorPlace6 days ago

    Forward Guidance Will Make or Break JNJ Earnings

    Johnson & Johnson (NYSE:JNJ) announces earnings on Tuesday before market open. The New Brunswick, New Jersey-based healthcare company has become one of the strongest, longest-running brands in existence.Source: Shutterstock However, challenges with drug patent expirations have blunted earnings growth in JNJ stock. This has left JNJ trading in a range for more than two years. Though this report will probably not deliver any meaningful surprises, investors still need signs that earnings growth will resume in Johnson & Johnson stock to break the equity out of its range. Pharma Will Drive the Report on JNJ StockTuesday's announcement will kick off earnings season for the pharma industry. Wall Street forecasts Q1 earnings to come in at $2.06 per share, matching the number for Q1 2018. They also predict revenues of $19.6 billion, a 2% decrease from the $20.01 billion announced in the same quarter last year.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 8 Risky Stocks to Watch as Earnings Season Kicks Off Consumers know JNJ best for its consumer health products. However, many often forget that medical devices and pharma each drive greater shares of the company's revenue. It is pain in the pharma division that's driving the predicted revenue decline.Sales of Simponi/Simponi Aria and Xarelto fell in the fourth quarter. The company has also cited alternatives to Velcade, Tracleer and Zytiga in explaining revenue declines. By no means is JNJ stock the only pharma stock to struggle with new competition. AbbVie (NYSE:ABBV) faces the same issue with Humira. Also, Pfizer (NYSE:PFE) will see its patent protection go away in its blockbuster drug Lyrica this summer.Patent expirations have long affected pharma stocks, and this may have helped to trap JNJ stock in a range. Since early 2017, JNJ stock has traded near the $120 per share to $150 per share range. Now, its forward P/E ratio comes in below 15. In the past few years, JNJ's forward P/E has typically been in the high teens to the low 20s.The stagnant earnings may explain the modest discount in JNJ stock. For this reason, I think investors will focus on guidance in the upcoming report. As of now, Wall Street expects 2019 earnings to increase by 4.6%. In all likelihood, investors will need to at least see that figure to move JNJ higher. JNJ Stock Retains Numerous AdvantagesFortunately, some tailwinds could help JNJ stock. Traders should remember that JNJ stock usually beats estimates, at least on earnings. For that reason, I would expect the earnings number to come in higher than $2.06 per share.Also, JNJ stock should continue to deliver the stability for which the public knows the company. For now, JNJ and Microsoft (NASDAQ:MSFT) are the only two U.S. companies that maintain a AAA credit rating. Debt levels have fallen over the last year, so I see no change in that status coming.Also, attention should shift back to the dividend in the coming days. The company traditionally announces a hike to its JNJ stock dividend soon after the Q1 report. They have increased the payout every year since 1963. Hence, I do not see the company breaking its 56-year streak of payout increases. The only question remains how much of a dividend hike JNJ gives.Johnson & Johnson stock currently pays 90 cents per share each quarter, a yield of about 2.65%. In the past, earnings growth has had little obvious effect on the size of the increase. While I do not foresee any surprises, the dividend boost could help JNJ stock to recover. Concluding Thoughts on JNJ StockGoing into earnings, investors need to see guidance that will help break JNJ stock out of its range. Johnson & Johnson usually beats earnings. However, patent expirations on key drugs have led to modest declines in revenue. They may also explain why JNJ has traded in a range for the last two years.However, conditions increasingly point to the potential for a rising stock price. The P/E ratio has fallen below company averages. Moreover, analysts forecast earnings increases in later quarters and for the overall year. If company guidance confirms those predictions, JNJ stock should rise. An expected dividend hike in the coming weeks should offer further help. * 7 AI Stocks to Watch with Strong Long-Term Narratives JNJ stock trades at about $135 per share now. If guidance affirms or exceeds profit growth predictions, I think it could help take JNJ past $150 per share sooner rather than later.As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. You can follow Will on Twitter at @HealyWriting. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * FAANNG Stocks, Ranked From Cheapest to Most Expensive * 7 Stocks With a Lot on the Line This Earnings Season * 7 Marijuana Companies: Which Pot Stocks Should You Buy? Compare Brokers The post Forward Guidance Will Make or Break JNJ Earnings appeared first on InvestorPlace.

  • Do CEOs really make 100 times more than employees? They do at these big U.S. companies
    American City Business Journals6 days ago

    Do CEOs really make 100 times more than employees? They do at these big U.S. companies

    Across the country, numerous CEOs at many of the largest U.S. companies in 2018 were paid 100, 200, 300, 400, 500 or 600 times as much as their company's median employee.

  • AbbVie's MAVIRET™ now reimbursed in Quebec
    CNW Group7 days ago

    AbbVie's MAVIRET™ now reimbursed in Quebec

    AbbVie's MAVIRET™ now reimbursed in Quebec

  • Here's what to expect from the stock market next month
    Investopedia8 days ago

    Here's what to expect from the stock market next month

    History favors a sustained rally after the strongest first quarter in a decade, but challenges remain as growth slows in the U.S., China and Europe.

  • J&J (JNJ) to Kick-start Pharma Q1 Earnings: What's in Store?
    Zacks8 days ago

    J&J (JNJ) to Kick-start Pharma Q1 Earnings: What's in Store?

    J&J's (JNJ) sales growth in first-quarter 2019 is expected to be hurt by generic/biosimilar headwinds in the Pharma unit.

  • AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know
    Zacks10 days ago

    AbbVie (ABBV) Outpaces Stock Market Gains: What You Should Know

    In the latest trading session, AbbVie (ABBV) closed at $83.98, marking a +0.64% move from the previous day.

  • J&J Stock on an Uptrend This Year So Far: More Room to Run?
    Zacks10 days ago

    J&J Stock on an Uptrend This Year So Far: More Room to Run?

    J&J (JNJ) performs better than the industry in 2019 so far and looks well poised to sustain the momentum in the rest of the year.

  • Better Buy: AbbVie vs. Johnson & Johnson
    Motley Fool11 days ago

    Better Buy: AbbVie vs. Johnson & Johnson

    Which of these healthcare titans is the better investment today? The answer might surprise you.

  • GuruFocus.com13 days ago

    AbbVie: High-Yield Dividend Aristocrat Offering a No-Fee DRIP

    Dividend growth investing has proven to be one of the best ways for retail investors to accumulate wealth over the long term. One of the factors that boosts the wealth-creating power of dividend growth investing, is dividend reinvestment. Dividend reinvesting makes one's share count rise, even if there is no additional principal invested into new shares.

  • Top Stock Reports for Boeing, Lockheed Martin & Anthem
    Zacks13 days ago

    Top Stock Reports for Boeing, Lockheed Martin & Anthem

    Top Stock Reports for Boeing, Lockheed Martin & Anthem

  • 10 Medical Marijuana Stocks to Cure Your Portfolio
    InvestorPlace14 days ago

    10 Medical Marijuana Stocks to Cure Your Portfolio

    Invariably, no other investment class generates as much interest and controversy as marijuana stocks. Within a generation, public sentiment toward legalization shifted dramatically from strongly opposed to mostly supportive. This is largely due to demographics, as the more progressive millennials replace older Americans in positions of influence.Additionally, marijuana stocks represent a viable economic channel that can help bridge the gap for many states' financial issues. For instance, green-friendly Colorado enjoys significant tax revenues from their botanical industry. I don't see this trend changing for the worse anytime soon, as awareness and popularity is only increasing.Of course, cannabis isn't without its controversies. Primarily, the federal government classifies marijuana as a Schedule I drug, putting it on par with hardcore narcotics like cocaine. Thus, no matter how liberal some states become toward their agricultural ambitions, the specter of federal oversight and crackdowns keeps many entrepreneurs and businesses away.InvestorPlace - Stock Market News, Stock Advice & Trading TipsHowever, we have one critical exception to the rule: marijuana stocks that specialize in medicinal and therapeutic benefits. For one thing, medical cannabis mitigates the stereotypical image of potheads and general no-gooders. Plus, people experiment with pharmaceuticals all the time. Why not allow these same patients the choice for natural alternatives?More critically for marijuana stocks, the medicinal aspect offers the best chance for international acceptance. Currently, very few jurisdictions allow recreational weed. Given the abundance of traditional and conservative nations, a green world is unlikely. But as Thailand and South Korea demonstrated, medical cannabis is a much easier sell. * 7 Biometric Stocks to Watch as AI Rises As a result, you want exposure not just to marijuana stocks, but also to the therapeutic element. Here are 10 names to consider: Medical Marijuana Stocks: AbbVie (ABBV)Source: Shutterstock Whenever you have a discussion about cannabis stocks, chances are, AbbVie (NYSE:ABBV) isn't the first name you think about. One of the healthcare sector's blue chips, ABBV stock has soared on its vast therapeutic pipeline. We're talking mainstream solutions for common ailments and diseases like arthritis and plaque psoriasis.Still, AbbVie maintains some botanical credibility with its Marinol therapy. A synthetic cannabis-based drug, Marinol addresses chemotherapy-related side effects, such as vomiting or nausea. In addition, it helps restore appetite among AIDS patients.Of course, you should note that Marinol isn't among AbbVie's top-selling products. Therefore, you're only getting limited exposure to cannabis with ABBV stock. But based on the extreme volatility of marijuana stocks, that isn't such a bad gig. Emerald Health Therapeutics (EMHTF)Source: Shutterstock Not that I would know, but growing cannabis allegedly isn't rocket science. With the right conditions, the right equipment and a reasonable car, anyone can grow their stash. But cultivating the plant so that it addresses specific ailments and symptoms? That takes real effort, which is where Emerald Health Therapeutics (OTCMKTS:EMHTF) comes in.Rather than just pumping out the green stuff, Emerald deliberately seeks out the strains most effective in addressing patients' needs. The company provides a wide selection of strains, which range in weight, tetrahydrocannabinol (THC) content, and cannabidiol (CBD) strength. Their impressive portfolio should lift EMHTF stock over the long run, as interest in CBD products accelerates. * The Elite 8 Stocks to Buy for Massive Outperformance More importantly, the markets share the same opinion. On year-to-date basis, EMHTF stock is up nearly 70%. While all cannabis stocks suffer volatility risk, Emerald's concentration on medicinal weed should help mitigate downside pressure. Aurora Cannabis (ACB)Source: Shutterstock I've spent a lot of time discussing Aurora Cannabis (NYSE:ACB), and I don't mean to keep double-dipping into this company. Still, I keep going back for a reason: ACB stock is an excellent play within the medical-marijuana market.A key factor in my bullishness for Aurora is their management team. In my view, they're making smart decisions through their acquisitive strategy. Rather than merely focusing on outright capacity, they're looking out over the horizon. Aurora's buyout of Whistler Medical Marijuana gave the organization significant leverage in medical cannabis due to Whistler's extensive genetics bank.Furthermore, ACB stock is a strong performer. Since the January opener, shares have skyrocketed roughly 70%. While it's likely to cool off, the inevitable correction should be only temporary. Among marijuana stocks, Aurora is exceptionally well-positioned for sustainable growth. Cronos Group (CRON)Source: Shutterstock One of the top names among major marijuana stocks, Cronos Group (NASDAQ:CRON) naturally attracts a lot of attention. This time, though, they're attracting the wrong kind.Prior to its earnings report for the fourth quarter, I worried about the company's revenue target. Hit or exceed it, and management can stave off criticism. But fall short, and CRON stock could crumble. They missed the sales target -- quite badly, too -- and shares naturally reacted poorly.But speculators looking for a discounted price may want to put CRON stock back on their radar. Since the beginning of March, Cronos has shed over 16%. However, the magnitude of volatility has declined noticeably in the past few days. * 10 Tech Stocks That Transformed Their Business Plus, Cronos has international legitimacy among medicinally focused cannabis stocks. Featuring partnerships and joint ventures across five continents, the company is ahead of the game. CannTrust (CTST)Source: Shutterstock In business -- even the green kind -- you can't get ahead of yourself. So while lucrative opportunities exist in the international sector, CannTrust (NYSE:CTST) remains firmly committed to winning its native Canadian market.At the same time, CannTrust can't afford to ignore the rest of the world. Although Canada becoming the first G7 nation to legalize recreational weed generated headlines, our northern neighbors alone can't support this burgeoning industry. Therefore, management has focused on the growth and capacity narrative to compete effectively at home and, later, abroad.To achieve the second leg of this journey, CannTrust teamed up with Denmark's Stenocare to distribute medical-cannabis products in that country. It also inked a partnership with an Australian firm for similar distribution arrangements. While it's not the most common name among marijuana stocks, CTST stock provides a risky, but viable, opportunity. Innovative Industrial Properties (IIPR)Source: Shutterstock Most marijuana stocks focus on the industry's front face; namely, production. As I mentioned earlier, marijuana isn't that difficult to grow. So long as you have the green light legally, the physical barrier to entry is relatively short.But the real challenge, though, is finding a consistent source of financing. This is where Innovative Industrial Properties (NYSE:IIPR) lends a helping hand. Despite momentum toward legalization, several financial institutions shy away from cannabis ventures. Innovative Industrial plugs the gap, offering critical capital through its leaseback business model. * 8 Genomic Testing Stocks That Can Ease the Sting of Theranos Thanks to the company's tremendous utility, IIPR stock has lit up the markets. Shares are currently up 66% YTD. Technically, IIPR may have gotten a bit overheated. That said, I wouldn't get too greedy looking for the perfect entry point. Innovative Industrial levers a proven business model that is only increasing in relevancy. Terra Tech (TRTC)Source: Shutterstock Everyone recognizes cannabis stocks for two things: their incredible potential and their equally incredible volatility. Unfortunately, stakeholders of medical-cannabis producer Terra Tech (OTCMKTS:TRTC) find themselves in the latter category. Over the trailing year, TRTC stock is down around 60%.And the bad news doesn't end there. Unlike many other marijuana stocks, Terra Tech has had trouble generating top-line growth. In its most recent earnings report for the fourth quarter, the company reported $6.92 million in sales. This badly underperformed against the year-ago level, when Terra Tech generated revenue of $11 million.So why take a bet on TRTC stock? First, its vertically integrated organization may facilitate significant efficiencies as political momentum increases. Second, I dig their leadership team. The head execs are experts in finance, which should prove beneficial in properly navigating TRTC across choppy waters. Charlotte's Web (CWBHF)Source: Shutterstock When most people look at Charlotte's Web (OTCMKTS:CWBHF), they're thinking that they missed the boat. After all, CWBHF stock has jumped almost 113% since the beginning of this year. From the opening price of April, Charlotte's Web shares gained a ridiculous 16%.As much as I love marijuana stocks, I'm fairly certain that this cannabis firm is due for a pullback. But once that occurs, I wouldn't waste too much time squabbling over the granularity. Instead, I'd consider what our own Matt McCall had to say. Thanks to the popularity of CBD, Charlotte's Web's CBD-based products could be distributed across mainstream retail channels. * 7 Reasons Americans Should Embrace Socialism Unquestionably, such an event would launch CWBHF stock into the stratosphere. Moreover, because most CBD products contain no trace of THC, they don't fall under severe federal guidelines. Therefore, don't get too greedy looking for an ideal price point when CWBHF corrects. Cannabis Science (CBIS)Source: Shutterstock On paper, Cannabis Science (OTCMKTS:CBIS) represents the next evolution among cannabis stocks: pharmaceutical firms that devote their time and research exclusively toward medical marijuana. Not only that, this is a much-needed development that could lift CBIS stock, as well as the entire botanical industry.For decades, people unquestionably trusted the mainstream healthcare and pharmaceutical network. However, the rapidly escalating opioid crisis has proven that well-intentioned medical professionals can lever a tragic impact. One of the underlying causes of this crisis is the addictiveness of prescribed medicines.Organizations like Cannabis Science can potentially mitigate this situation with naturally sourced therapies free of psychoactive side-effects. That's the allure for CBIS stock. However, shares trade for less than 3 cents a pop, so this is only for the risk-tolerant. GW Pharmaceuticals (GWPRF)Source: Shutterstock On surface level, GW Pharmaceuticals (OTCMKTS:GWPRF) brings a lot of positives to the table. As pioneers among medicinally-concentrated marijuana stocks, they lever substantial credibility. Their Sativex drug for addressing symptoms associated with multiple sclerosis achieved better-than-expected results. This only encourages other companies to pursue cannabis-based therapies for many other diseases.That's the good news. The not-so-pleasant side of the coin, though, is market performance. While no one mistakes cannabis stocks as stable investment platforms, GWPRF stock is rough for even hardened botanical veterans. In December of last year, shares fell off a cliff before rebounding back toward low-earth orbit. * 7 Biometric Stocks to Watch as AI Rises So is GWPRF stock worth a look now? Although I like how the company has stabilized, I don't care for its low volume. But GW Pharmaceuticals is a penny stock with underappreciated talents. If you have the nerve and the patience, it's worth your consideration.As of this writing, Josh Enomoto did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 Low-Priced Tech Stocks With Great Potential * 9 Stocks That Would Be Hurt By a Mexico/U.S. Border Closure * The Era of Car Ownership Is Over. And These 4 Charts Prove It Compare Brokers The post 10 Medical Marijuana Stocks to Cure Your Portfolio appeared first on InvestorPlace.

  • AbbVie Announces New Formulary Listings for its Hepatitis C Treatment MAVIRET™
    CNW Group14 days ago

    AbbVie Announces New Formulary Listings for its Hepatitis C Treatment MAVIRET™

    AbbVie Announces New Formulary Listings for its Hepatitis C Treatment MAVIRET™

  • Novartis Resubmits BLA to FDA for Biosimilar of Neulasta
    Zacks14 days ago

    Novartis Resubmits BLA to FDA for Biosimilar of Neulasta

    Novartis' (NVS) generic arm Sandoz resubmits its BLA for the proposed biosimilar of Neulasta.

  • Alector (ALEC) Initiates Phase I Alzheimer's Study on AL003
    Zacks15 days ago

    Alector (ALEC) Initiates Phase I Alzheimer's Study on AL003

    Alector, Inc. (ALEC) initiates the phase I INTERCEPT study on AL003 for the treatment of Alzheimer???s disease.